IgG Fc binding protein (FCGBP) inhibits the development of laryngeal squamous cell carcinoma and cisplatin resistance through the PIGR/JAK2/STAT3 pathway

Wan, Xuemei; Zeng, Yunlan; Xiong, Ming; Chen, Lin; Bai, Yundan

doi:10.2478/raon-2026-0003

.blurhash-client-img { display: none !important; }

IgG Fc binding protein (FCGBP) inhibits the development of laryngeal squamous cell carcinoma and cisplatin resistance through the PIGR/JAK2/STAT3 pathway

Radiology and Oncology

AHEAD OF PRINT

By: Xuemei Wan, Yunlan Zeng, Ming Xiong, Lin Chen and Yundan Bai

Open Access

|Jan 2026

Authors

Xuemei Wan

Department of Otolaryngology Head and Neck Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, China

Department of Otolaryngology, Chengdu Integrated TCM & Western Medicine Hospital, Chengdu, China

Yunlan Zeng

Department of Otolaryngology, Chengdu Integrated TCM & Western Medicine Hospital, Chengdu, China

Ming Xiong

Department of Otolaryngology, Chengdu Integrated TCM & Western Medicine Hospital, Chengdu, China

Lin Chen

Department of Otolaryngology, Chengdu Integrated TCM & Western Medicine Hospital, Chengdu, China

Yundan Bai

byd1987@126.com

Department of Otolaryngology Head and Neck Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, China

Department of Otolaryngology, Chengdu Integrated TCM & Western Medicine Hospital, Chengdu, China

DOI: https://doi.org/10.2478/raon-2026-0003 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099

Journal RSS Feed

Language: English

Submitted on: Jun 20, 2025

Accepted on: Jul 25, 2025

Published on: Jan 21, 2026

Published by: Association of Radiology and Oncology

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

laryngeal squamous cell carcinoma,

FCGBP,

Related subjects:

Haematology, oncology,

Radiology

© 2026 Xuemei Wan, Yunlan Zeng, Ming Xiong, Lin Chen, Yundan Bai, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.

AHEAD OF PRINT